uniQure (NASDAQ:QURE) Price Target Raised to $70.00

uniQure (NASDAQ:QURE) had its target price upped by HC Wainwright from $25.00 to $70.00 in a report released on Monday,Benzinga reports. The firm currently has a buy rating on the biotechnology company’s stock. HC Wainwright also issued estimates for uniQure’s Q4 2024 earnings at ($0.75) EPS, FY2024 earnings at ($4.17) EPS, Q1 2025 earnings at ($0.66) EPS, Q2 2025 earnings at ($0.72) EPS, Q3 2025 earnings at ($0.75) EPS, Q4 2025 earnings at ($0.85) EPS, FY2025 earnings at ($2.99) EPS, FY2026 earnings at ($1.80) EPS, FY2027 earnings at $6.91 EPS, FY2028 earnings at $16.97 EPS and FY2029 earnings at $18.47 EPS.

Several other research analysts also recently weighed in on the stock. Stifel Nicolaus upped their target price on shares of uniQure from $12.00 to $32.00 and gave the stock a “buy” rating in a report on Monday, December 16th. Leerink Partners increased their target price on uniQure from $26.00 to $44.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 11th. Guggenheim reissued a “buy” rating on shares of uniQure in a report on Wednesday, December 11th. Cantor Fitzgerald lifted their price objective on shares of uniQure from $28.00 to $58.00 and gave the company an “overweight” rating in a research report on Tuesday, December 10th. Finally, The Goldman Sachs Group upped their target price on shares of uniQure from $9.00 to $20.00 and gave the stock a “neutral” rating in a research report on Thursday, December 12th. One analyst has rated the stock with a sell rating, two have issued a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $40.00.

uniQure Stock Performance

NASDAQ:QURE opened at $15.24 on Monday. The stock has a 50-day simple moving average of $13.31 and a two-hundred day simple moving average of $8.84. The company has a debt-to-equity ratio of 0.92, a quick ratio of 6.51 and a current ratio of 6.51. uniQure has a 52-week low of $3.73 and a 52-week high of $19.18. The firm has a market capitalization of $742.80 million, a PE ratio of -3.07 and a beta of 0.41.

uniQure (NASDAQ:QURE) last released its earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.12) by $0.21. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. The company had revenue of $2.29 million during the quarter, compared to analyst estimates of $2.73 million. Analysts forecast that uniQure will post -3.74 EPS for the current year.

Insider Activity

In other uniQure news, CEO Matthew C. Kapusta sold 3,418 shares of the company’s stock in a transaction that occurred on Monday, December 9th. The stock was sold at an average price of $7.63, for a total transaction of $26,079.34. Following the sale, the chief executive officer now directly owns 597,915 shares in the company, valued at $4,562,091.45. This represents a 0.57 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. Corporate insiders own 4.74% of the company’s stock.

Institutional Trading of uniQure

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. FNY Investment Advisers LLC bought a new position in uniQure during the fourth quarter valued at $88,000. RTW Investments LP bought a new position in uniQure during the 3rd quarter valued at about $49,000. China Universal Asset Management Co. Ltd. raised its position in uniQure by 57.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,093 shares of the biotechnology company’s stock worth $50,000 after purchasing an additional 3,663 shares during the period. Atria Investments Inc bought a new stake in uniQure in the third quarter worth about $53,000. Finally, Quarry LP purchased a new position in shares of uniQure during the third quarter valued at approximately $58,000. Hedge funds and other institutional investors own 78.83% of the company’s stock.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.